Status:

COMPLETED

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

Lead Sponsor:

Pfizer

Conditions:

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

To investigate safety and efficacy of single agent sunitinib malate in Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor.

Eligibility Criteria

Inclusion

  • Histologically-proven diagnosis of malignant GIST (Gastrointestinal Stromal Tumors).
  • Evidence of unidimensionally measurable disease
  • Failure of prior treatment with imatinib or intolerant to imatinib
  • Male or female, 18 years of age or older.
  • ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.
  • Resolution of all acute toxic effects
  • Adequate organ function.

Exclusion

  • Anticancer treatment after last dose of imatinib
  • Major surgery within 4 weeks or radiation therapy within 2 weeks.
  • Grade 3 hemorrhage within 4 weeks prior to starting the study treatment.
  • Diagnosis of second malignancy within the last 5 years.
  • History of brain disease.
  • Cardiac disease within 12 months.
  • Thyroid function abnormality.
  • Ongoing cardiac dysrhythmias.
  • Uncontrolled hypertension.
  • Ongoing treatment with anticoagulant and CYP3A4 inhibitors and inducers.
  • HIV or AIDS related illness.
  • Pregnancy or breastfeeding.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00793871

Start Date

November 1 2008

End Date

October 1 2014

Last Update

November 20 2015

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Nanjing Bayi Hospital

Nanjing, Jiangsu, China, 210002

2

Cancer Institute & Hospital Chinese Academy of Medical Sciences and PUMC

Beijing, China, 100021

3

Beijing Cancer Hospital

Beijing, China, 100035

4

307 Hospital of PLA

Beijing, China, 100071